$AMRS, The Amyris Inc. (AMRS) Given $2.63 Ave
Post# of 23119
Posted On: 11/29/2016 8:16:53 AM
$AMRS,
The Amyris Inc. (AMRS) Given $2.63 Average Target Price by Brokerages
November 29, 2016 Henry Williams
The Amyris Inc. (AMRS) Given $2.63 Average Target Price by Brokerages
Amyris Inc. (NASDAQ:AMRS) has been given an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
Brokerages have set a 12-month consensus price objective of $2.63 for the company and are predicting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Amyris an industry rank of 54 out of 265 based on the ratings given to related companies.
AMRS has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Wednesday, July 6th. Singular Research reissued a “buy” rating and issued a $2.80 price objective on shares of Amyris in a research note on Wednesday, September 28th.
Amyris (NASDAQ:AMRS) opened at 1.05 on Wednesday. The stock’s 50 day moving average price is $0.69 and its 200 day moving average price is $0.60. Amyris has a 12-month low of $0.31 and a 12-month high of $1.85. The company’s market capitalization is $246.77 million.
Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.06. The company had revenue of $9.60 million for the quarter, compared to the consensus estimate of $15.23 million. During the same period in the prior year, the firm posted ($0.47) EPS. The business’s revenue was up 23.1% on a year-over-year basis. On average, equities analysts anticipate that Amyris will post ($0.20) EPS for the current fiscal year.
In other Amyris news, major shareholder (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of Amyris stock in a transaction on Monday, October 17th. The shares were sold at an average price of $0.83, for a total value of $1,909,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 48.70% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. bought a new stake in shares of Amyris during the first quarter worth $269,000. Geode Capital Management LLC raised its stake in shares of Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock worth $331,000 after buying an additional 30,958 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares during the period. 35.68% of the stock is currently owned by institutional investors and hedge funds.
About Amyris
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
The Amyris Inc. (AMRS) Given $2.63 Average Target Price by Brokerages
November 29, 2016 Henry Williams
The Amyris Inc. (AMRS) Given $2.63 Average Target Price by Brokerages
Amyris Inc. (NASDAQ:AMRS) has been given an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
Brokerages have set a 12-month consensus price objective of $2.63 for the company and are predicting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Amyris an industry rank of 54 out of 265 based on the ratings given to related companies.
AMRS has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Wednesday, July 6th. Singular Research reissued a “buy” rating and issued a $2.80 price objective on shares of Amyris in a research note on Wednesday, September 28th.
Amyris (NASDAQ:AMRS) opened at 1.05 on Wednesday. The stock’s 50 day moving average price is $0.69 and its 200 day moving average price is $0.60. Amyris has a 12-month low of $0.31 and a 12-month high of $1.85. The company’s market capitalization is $246.77 million.
Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.06. The company had revenue of $9.60 million for the quarter, compared to the consensus estimate of $15.23 million. During the same period in the prior year, the firm posted ($0.47) EPS. The business’s revenue was up 23.1% on a year-over-year basis. On average, equities analysts anticipate that Amyris will post ($0.20) EPS for the current fiscal year.
In other Amyris news, major shareholder (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of Amyris stock in a transaction on Monday, October 17th. The shares were sold at an average price of $0.83, for a total value of $1,909,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 48.70% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. bought a new stake in shares of Amyris during the first quarter worth $269,000. Geode Capital Management LLC raised its stake in shares of Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock worth $331,000 after buying an additional 30,958 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares during the period. 35.68% of the stock is currently owned by institutional investors and hedge funds.
About Amyris
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'